f ? 0 = f X t=1 ((t ? t?1) f X t=1 (Cost t (Ext) ? (k + 1) Cost t (OPT)) = Cost(Ext) ? (k + 1) Cost(OPT) : By Lemma 10 and the last equation we conclude that Cost(Ext) (2k + 1) Cost(OPT) + O(1) : Lemma 6 now implies that WFA is (4k + 1)-competitive. 13 Claim 2: Suppose the adversary moves a server from u j to v, and let d = u j v > 0. Then, ? t ? t?1 ?(k + 1)d : Proof: Since ? t depends on the ...

This dissertation is about sensor networks, and connection oriented communication. We present an overview of the field of sensor networks, and advocate the use of connection oriented communication technologies, such as spread spectrum radios. We claim that low duty sensor networks should use frequency synchronized radios. We additionally claim that low duty operation on a single channel is actu...

The duration of a buyer’s claim for remedies is a frequent source of negotiations in private contracts, and is a contested contract law issue. Disagreement concerns even the basic issue as to whether a rationale exists at all for cutting o¤ the buyer’s claim some time after purchase. The present article argues that a rationale can be given for cutting of the buyer’s claim, and sets forth the fa...

With so much discussion about claim benchmarking, treatment protocols and the like, did you ever wish someone couldjust point you in the right direction? This analysis o)Cthe detailed workers compensation [WC] claim data now becoming available to researchers leads to a picture that resembles a simplified navigational chart. As described in the paper, that map--together with a few rules--provide...

OBJECTIVE To determine the cost-effectiveness of Assertive Community Treatment (ACT) in comparison to Standard Case Management (SCM) for persons with severe mental illness and substance use disorders. DATA SOURCES AND STUDY SETTING Original data on the effectiveness and social costs of ACT and SCM that were collected between 1989 and 1995. Seven community mental health centers in New Hampshir...

Two new drugs provide startling benefits in the treatment of age-related macular degeneration (AMD). The clinical and cost effectiveness of ranibizumab (Lucentis) was compared to that of bevacizumab (Avastin), which costs up to 100 times less. A cost effectiveness model was developed to assess the cost per quality adjusted life year (QALY) over 10 years. For predominantly classic AMD, the effic...

An elementary step in drug policy analysis is comparing the cost of an intervention to its benefit in the form of the social cost averted because of reduced drug use and associated consequences. One would think that cost of illness (COI) studies would provide a solid foundation for quantifying the benefits of reduced drug use, but at present they do not. This paper suggests ways the COI studies...

G reimbursed for the services you provide should be fairly straightforward: provide a service, submit a claim, and receive payment. It sounds simple enough, but a lot can go wrong in this process, from coding and data entry errors made by your practice to complex coding edits made by your payers. The American Medical Association’s most recent National Health Insurer Report Card found that the m...